Many great presentations this week at EULAR 2021 will feature industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
All News
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Methotrexate Impairs COVID Vax Response
One-third of patients with immune-mediated inflammatory diseases being treated with methotrexate showed attenuated responses to the COVID-19 vaccine, researchers reported.
The Swedish Register compared outcomes of 1502 rheumatoid arthritis (RA) patients initiating either biologics plus methotrexate (MTX) or triple therapy (MTX plus sulfasalazine plus hydroxychloroquine/chloroquine) and showed similar rates of sustained remission.
JAMA Internal Medicine report an analysis of recent and composite trial data suggesting that tocilizumab (TCZ) therapy in COVID-19–associated pneumonia patients with high CRP levels is likely to be effective.
House lawmakers on both sides of the aisle pummeled AbbVie CEO Richard Gonzalez for raising the price of two widely used drugs and for the company's "legally questionable" tactics to head off competition from biosimilars, despite pulling in healthy profits.
Analysis of data from the COVID-19 Global Rheumatology Alliance shows that rheumatic diseases infected with COVID-19 had a greater risk of death with age, comorbidities, high disease activity and few specific therapies.
